10 news items
Updated Linvoseltamab Data Showcase Continued Deepening of Responses in Patients with Heavily Pre-Treated Multiple Myeloma
REGN
16 Jun 24
® technologies to develop medicines for patients with diverse blood cancers and rare blood disorders. Our blood cancer research
Navigating 14 Analyst Ratings For Regeneron Pharmaceuticals
REGN
4 Jun 24
(NASDAQ:REGN), offering a diverse set of opinions from bullish to bearish.
The table below provides a snapshot of their recent
Biohaven Doses First Patient with its Novel Trop-2 Directed Antibody Drug Conjugate (ADC) BHV-1510 in Advanced or Metastatic Epithelial Tumors
BHVN
REGN
29 May 24
deep in-house expertise in oncology clinical development, ADC chemistry, and complex manufacturing, we believe our diverse and growing ADC portfolio
More than $9 Million Awarded to High School Scientists and Engineers at the Regeneron International Science and Engineering Fair 2024
REGN
17 May 24
and determination shown by these remarkable students. Coming from around the world with diverse backgrounds and academic disciplines, these students have
More than $9 Million Awarded to High School Scientists and Engineers at the Regeneron International Science and Engineering Fair 2024
REGN
17 May 24
by the ingenuity and determination shown by these remarkable students. Coming from around the world with diverse backgrounds and academic disciplines
6iye96qtjlr9x9n 4ge6lgzlditdwpc6r14uhyq04g
REGN
17 May 24
by the ingenuity and determination shown by these remarkable students. Coming from around the world with diverse backgrounds and academic disciplines
i1pxt l0c
REGN
24 Apr 24
multiple promising and distinct investigational treatment approaches for a diverse array of difficult-to-treat cancers," said George D. Yancopoulos
fz0nsrfr
REGN
12 Apr 24
(NASDAQ:REGN) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The following table encapsulates
sshm4ic0slghfrb40isk3u658vjien48h 8x0
REGN
7 Apr 24
VelociSuite® technologies to develop medicines for patients with diverse blood cancers and rare blood disorders. Our blood
5l0keycbekli2j5lo rb07z0jhmm43cmqs4
REGN
26 Mar 24
(NASDAQ:REGN) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The table below provides a snapshot
- Prev
- 1
- Next